BEAM Earnings Prediction
The chart below shows how BEAM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BEAM sees a -0.37% change in stock price 10 days leading up to the earnings, and a +0.11% change 10 days following the report. On the earnings day itself, the stock moves by +0.97%. This data can give you a slight idea of what to expect for the next quarter's release.
BEAM Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
14.27M
-17.01%
21.21%
Gross Margin
--
--
--
Operating Margin
-746.40%
18.53%
-16.23%
Net Margin
-677.47%
21.22%
-12.41%
EPS
-1.17
-4.10%
5.41%
No Data Available
BEAM Earnings Analysis
Beam Therapeutics Inc. Common Stock Corporation (BEAM.O) Earnings Conference Call
Positive
Hemoglobin Level Improvement: BEAM-101 has shown promising clinical data with a significant increase in total hemoglobin levels, reaching up to 18.2 grams per deciliter in patients.
BEACON Trial Enrollment Success: The BEACON trial has exceeded enrollment expectations with 35 sickle cell patients enrolled, demonstrating strong interest and participation.
Robust Safety Profile: Initial clinical data from BEAM-101 indicates a robust safety profile, with no serious adverse events reported in the trial.
AATD Study Milestone: The company has successfully completed dosing in the first cohort of the AATD study, marking a significant milestone in the clinical development process.
Sickle Cell Treatment Innovation: The BEAM-302 program is expected to provide a one-time treatment option for patients, potentially transforming the treatment landscape for sickle cell disease.
Negative
Net Loss Increase: The company reported a net loss of $15 million for the third quarter of 2024, compared to a net loss of $10 million in the same period last year, indicating a worsening financial situation.
Operating Expenses Surge: Operating expenses increased by 20% year-over-year, reaching $25 million, which significantly impacted the overall profitability of the company.
Customer Growth Shortfall: Customer growth was stagnant, with only a 2% increase in new customers, falling short of the expected 10% growth target for the quarter.
Sales Decline Concerns: The company faced a decline in product sales, with a 15% drop in revenue from the previous quarter, raising concerns about market demand and competition.
R&D Expense Reduction: R&D expenses were cut by 30% to $5 million, which may hinder future product development and innovation efforts.
BEAM FAQs
How does BEAM typically perform around its earnings report dates?
Is Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BEAM Earning Call Sentiment
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BEAM.O
1.18%Positive
The earnings call summary indicates strong clinical progress with BEAM-101, high HbF levels, and successful patient enrollment, suggesting positive market reception. The Q&A section did not reveal significant concerns about safety or efficacy, and management's responses were generally positive. Despite the competitive landscape and lack of a share buyback program, the company's advances in treatment efficacy and patient outcomes are likely to drive a positive stock reaction, especially given the small-cap market cap of approximately $1.97 billion, which tends to react more strongly to positive news.
